Cartesian Therapeutics, Inc.
No SEC Form 4 filings for $RNAC in the last 30 days.
See all $RNAC insider activity →Cartesian Therapeutics (RNAC) granted options for 121,900 shares to four new employees. The options have a $7.22 exercise price and vest over four years. The company is in late-stage clinical trials for autoimmune disease treatments, including Descartes-08 for generalized myasthenia gravis.
Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retre
Cartesian Therapeutics (RNAC) reported additional retreatment data for Descartes-08, showing a mean MG-ADL reduction of 6.6 points at Month 12. The median interval between initial treatment and retreatment was 16.6 months. No new safety signals were reported. Topline Phase 3 AURORA trial data is expected in 1Q27.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RNAC (Cartesian Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent RNAC coverage spans technology, financial news and corporate actions.
The option grant may cause slight dilution and modest downward pressure on the stock.
Positive retreatment results suggest durable efficacy and safety, likely boosting investor confidence.
Positive Phase 2b retreatment results may boost investor confidence ahead of the Phase 3 AURORA readout.
Near-term catalysts are clustered in 1H27 to 1Q27 (multiple trial data windows) and funding runway is extended into 2028 via non-dilutive credit.
New financing runway plus multiple upcoming clinical readouts can re-rate near-term risk and liquidity expectations for RNAC.
AlphAI scores every news story that mentions RNAC with an AI model for sentiment and relevance, and aggregates insider trades from Cartesian Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cartesian Therapeutics (RNAC) granted options for 121,900 shares to four new employees. The options have a $7.22 exercise price and vest over four years. The company is in late-stage clinical trials for autoimmune disease treatments, including Descartes-08 for generalized myasthenia gravis.
1 min readCartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retre
2 min readCartesian Therapeutics (RNAC) reported additional retreatment data for Descartes-08, showing a mean MG-ADL reduction of 6.6 points at Month 12. The median interval between initial treatment and retreatment was 16.6 months. No new safety signals were reported. Topline Phase 3 AURORA trial data is expected in 1Q27.
3 min readCartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 results and a business update. Phase 3 AURORA for Descartes-08 in myasthenia gravis continues, with data expected in 1Q27 and a BLA planned for mid-2027. Phase 2 TRITON myositis and Phase 1/2 HELIOS pediatric trials remain on track for 1H27 data. Cash was $149.3M at June 30, 2026, supporting operations into 2028.
4 min readCartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-20
6 min readCartesian Therapeutics (NASDAQ: RNAC) said it granted inducement stock options to eight new employees on July 1, 2026. The options cover 238,700 shares at a $10.18 exercise price (the Nasdaq close that day). Vesting is 25% on July 1, 2027, then monthly through July 1, 2030; options expire after 10 years.
2 min readCartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rnac-20260612 0001453687 false 0001453687 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readCartesian Therapeutics (NASDAQ:RNAC) rose after licensing its in vivo CAR-T platform to WestGene, with an upfront payment and potential development/commercial milestones, the company said. The partnership targets a myasthenia gravis trial in 2H 2026 and data in 1H 2027. Shares were about $6.90, up 17.75% Tuesday, per Benzinga Pro. Analysts rate Buy with an average $29.75 target.
7 min readCartesian Therapeutics (NASDAQ: RNAC) said it signed a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases, combining WestGene’s targeted LNP delivery with Cartesian’s mRNA payloads from Descartes-08. A Phase 1 dose-escalation study in generalized myasthenia gravis is expected to start in 2H 2026, with data in 1H 2027. WestGene will receive an upfront payment plus potential milestones.
4 min readNeedham & Company lowered its Cartesian Therapeutics (NASDAQ: RNAC) price target to $40 from $42 while keeping a “buy” rating, according to a Tuesday note reported by Benzinga. RNAC traded at $6.38, down 5.5%. The company reported Q1 EPS of -$1.46 and revenue of $0.08M, missing consensus.
3 min read
